Literature DB >> 7603913

Tumor suppressor gene p53 mutations in human prostate cancer.

Y Kubota1, T Shuin, H Uemura, K Fujinami, H Miyamoto, S Torigoe, Y Dobashi, H Kitamura, Y Iwasaki, K Danenberg.   

Abstract

The genetic background underlying the growth and development of human prostatic cancer is not yet clear. Here we searched for possible mutations in the entire coding region of tumor suppressor gene p53 in primary human prostatic carcinomas, using polymerase chain reaction and single-strand conformational polymorphism analysis of RNA. We found p53 gene mutations in 4 of 21 cases (19%). DNA sequencing of the polymerase chain reaction products revealed missense point mutations that resulted in amino acid changes in exon 5 or 3 in three cases and single base deletions in exon 7 in two cases. One case contained both a missense point mutation and a single base deletion. Three of these four cases were pathologically diagnosed as poorly differentiated adenocarcinomas, and three of the four cases were clinically localized to stage C or D. None of seven noncancerous prostate tissues nor three well-differentiated adenocarcinoma tissues showed any mutations. The present results suggest that p53 gene mutation is involved in the late progression steps of human prostate carcinogenesis.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7603913     DOI: 10.1002/pros.2990270105

Source DB:  PubMed          Journal:  Prostate        ISSN: 0270-4137            Impact factor:   4.104


  11 in total

Review 1.  Molecular markers for prostate cancer metastasis. Developing diagnostic methods for predicting the aggressiveness of prostate cancer.

Authors:  J T Isaacs
Journal:  Am J Pathol       Date:  1997-05       Impact factor: 4.307

Review 2.  Molecular staging of prostate cancer in the year 2007.

Authors:  Thorsten Schlomm; Andreas Erbersdobler; Martina Mirlacher; Guido Sauter
Journal:  World J Urol       Date:  2007-03-02       Impact factor: 4.226

3.  Mutations in the p53 Tumor Suppressor Gene: Important Milestones at the Various Steps of Tumorigenesis.

Authors:  Noa Rivlin; Ran Brosh; Moshe Oren; Varda Rotter
Journal:  Genes Cancer       Date:  2011-04

Review 4.  Molecular biology of prostate cancer.

Authors:  X B Shi; P H Gumerlock; R W deVere White
Journal:  World J Urol       Date:  1996       Impact factor: 4.226

5.  Prostate Cancer - Old Problems and New Approaches. (Part II. Diagnostic and Prognostic Markers, Pathology and Biological Aspects).

Authors:  Kenneth V Honn; Amer Aref; Yong Q Chen; Michael L Cher; John D Crissman; Jeffrey D Forman; Xiang Gao; David Grignon; Maha Hussain; Arthur T Porter; Edson J Pontes; Bruce Redman; Wael Sakr; Richard Severson; Dean G Tang; David P Wood
Journal:  Pathol Oncol Res       Date:  1996       Impact factor: 3.201

6.  Proliferation- and apoptosis-associated factors in advanced prostatic carcinomas before and after androgen deprivation therapy: prognostic significance of p21/WAF1/CIP1 expression.

Authors:  G B Baretton; U Klenk; J Diebold; N Schmeller; U Löhrs
Journal:  Br J Cancer       Date:  1999-05       Impact factor: 7.640

Review 7.  Molecular pathways and targets in prostate cancer.

Authors:  Emma Shtivelman; Tomasz M Beer; Christopher P Evans
Journal:  Oncotarget       Date:  2014-09-15

8.  Nuclear iASPP may facilitate prostate cancer progression.

Authors:  E V Morris; L Cerundolo; M Lu; C Verrill; F Fritzsche; M J White; G N Thalmann; C S ten Donkelaar; I Ratnayaka; V Salter; F C Hamdy; X Lu; R J Bryant
Journal:  Cell Death Dis       Date:  2014-10-23       Impact factor: 8.469

9.  Identification of novel prostate cancer drivers using RegNetDriver: a framework for integration of genetic and epigenetic alterations with tissue-specific regulatory network.

Authors:  Priyanka Dhingra; Alexander Martinez-Fundichely; Adeline Berger; Franklin W Huang; Andre Neil Forbes; Eric Minwei Liu; Deli Liu; Andrea Sboner; Pablo Tamayo; David S Rickman; Mark A Rubin; Ekta Khurana
Journal:  Genome Biol       Date:  2017-07-27       Impact factor: 13.583

10.  Reactivation of mutant p53 by a dietary-related compound phenethyl isothiocyanate inhibits tumor growth.

Authors:  M Aggarwal; R Saxena; E Sinclair; Y Fu; A Jacobs; M Dyba; X Wang; I Cruz; D Berry; B Kallakury; S C Mueller; S D Agostino; G Blandino; M L Avantaggiati; F-L Chung
Journal:  Cell Death Differ       Date:  2016-06-03       Impact factor: 15.828

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.